title: [The place of new antihistamines in allergy management. Apropos of desloratadine].
abstract: Desloratadine, the active metabolite of loratadine, is a new antihistamine. Because of its anti allergy properties, desloratidine has an affinity for histamine receptors 25 to 100 times greater to those of the usual antihistamines, coupled with a capacity to inhibit the production of pro-inflammatory mediators. When evaluated in healthy volunteers, the half life of desloratadine has been estimated at 27 hours, which is comparable with a night time length of action. Many clinical studies made with patients suffering with allergic rhinitis or chronic idiopathic urticaria have shown a rapid symptom reduction, lasting 24 hours after first taking. This action was correlated with an improvement in socio-professional activity, sleep and quality of life in general. In patients suffering from allergic rhinitis, rhinomanometry showed a significant improvement in nasal congestion by desloratadine. The clinical advantages of desloratadine on antihistamines taken previously were measured in a study made on almost 48,000 patients, of whom 91% found its efficacity satisfactory. By its powerful action, coupled with an excellent tolerance profile, desloratadine represents a real therapeutic advance for allergic patients.
authors.affiliation: Laboratoire de biologie cellulaire, CHU d'Angers, 49033 Angers.
authors.forename: A
authors.initials: A
authors.lastname: Sabbah
mesh_terms: D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D006207:Half-Life; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000188:drug therapy*; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors; D018799:Intercellular Adhesion Molecule-1 / Q000187:drug effects; D008099:Liver / Q000378:metabolism; D017336:Loratadine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D015201:Meta-Analysis as Topic; D015337:Multicenter Studies as Topic; D010342:Patient Acceptance of Health Care; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000187:drug effects; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy; D012449:Safety; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy
chemical_list: D018926:Anti-Allergic Agents; D006634:Histamine H1 Antagonists; D018836:Inflammation Mediators; D011994:Recombinant Proteins; D018799:Intercellular Adhesion Molecule-1; D017336:Loratadine; C121345:desloratadine